Archemix, a developer of aptamer-based therapeutics, said this week that John Maraganore has been appointed to its board of directors.
Maraganore is currently president and CEO of Alnylam Pharmaceuticals.
LRN, a provider of corporate ethics, compliance, and governance solutions, said this week that it has appointed Alan Spoon to its board.
Spoon is managing general partner for Polaris Venture Partners, an institutional investor in Alnylam Pharmaceuticals.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
